CAFs with elevated VCAN levels promoted the proliferation, migration, and invasion of high-stemness adenocarcinoma cells via the MDK-NCL and MIF-CD74-CD44 signaling pathways, while also enhancing immune evasion and self-renewal. These results position VCAN as a potential new therapeutic target for STAD.

3 days ago

Journal

CD74 (CD74 Molecule) • VCAN (Versican)

A non-invasive secreted protein-based gene signature for prognostic stratification and tumor microenvironment assessment in gastric cancer. (PubMed, PeerJ)

We established a non-invasive 8-SPCG signature that may serve as a potential predictor for GC prognosis and TME features. SERPINE1 was identified as a promising mediator linking GC progression to CAFs interactions, supporting its further investigation as a therapeutic target.

4 days ago

Journal • Tumor mutational burden • Gene Signature

TMB (Tumor Mutational Burden) • EGF (Epidermal growth factor) • SERPINE1 (Serpin Family E Member 1) • IGFBP1 (Insulin Like Growth Factor Binding Protein 1) • IL1F10 (Interleukin 1 Family Member 10) • GCG (Glucagon)

Camrelizumab plus albumin-bound paclitaxel and S-1 as first-line treatment for patients with human epidermal growth factor receptor 2-negative advanced gastric or gastroesophageal junction adenocarcinoma: a phase 2 trial. (PubMed, Front Immunol)

Randomized controlled clinical trials are required to further demonstrate its efficacy and optimal application scenario. https://clinicaltrials.gov/study/NCT04675866?term=Hou%20Xinfang&rank=1, identifier NCT04675866.

4 days ago

Clinical • P2 data • Journal

HER-2 (Human epidermal growth factor receptor 2)

HER-2 negative

AiRuiKa (camrelizumab) • albumin-bound paclitaxel

The emerging role of SPHK1 at the immune-metabolic interface: a pan-cancer integrative analysis. (PubMed, Sci Rep)

Additionally, it functions as a novel "metabolic immune checkpoint" across multiple cancer types. SPHK1 may bridge sphingolipid metabolism with tumor immune suppression and represents a potential promising integrated target for metabolically informed immunotherapy strategies.

5 days ago

Journal • Tumor mutational burden • IO biomarker • Pan tumor

TMB (Tumor Mutational Burden) • MSI (Microsatellite instability) • SPHK1 (Sphingosine Kinase 1)

[Retracted] Downregulated microRNA‑200a promotes EMT and tumor growth through the Wnt/β‑catenin pathway by targeting the E‑cadherin repressors ZEB1/ZEB2 in gastric adenocarcinoma. (PubMed, Oncol Rep)

The Editor apologizes to the readership for any inconvenience caused. [Oncology Reports 29: 1579‑1587, 2013; DOI: 10.3892/or.2013.2267].

7 days ago

Journal

CDH1 (Cadherin 1) • MIR200A (MicroRNA 200a) • SNAI2 (Snail Family Transcriptional Repressor 2) • ZEB1 (Zinc Finger E-box Binding Homeobox 1) • ZEB2 (Zinc Finger E-Box Binding Homeobox 2)

INHBA, regulated by C/EBPβ, induces M2 macrophage polarization to promote tumor metastasis and growth via activating the PI3K/AKT pathway in gastric cancer. (PubMed, Br J Cancer)

High INHBA expression predicts poor survival of GC patients. INHBA, upregulated by C/EBPβ, induces M2 macrophage polarization to promote tumor metastasis and growth via activating PI3K/AKT pathway in GC. INHBA may be a potential therapeutic target for GC.

7 days ago

Journal

TGFB1 (Transforming Growth Factor Beta 1)

Novel syngeneic model of anti-mouse CLDN18.2 CAR -T therapy for gastric cancer demonstrates a synergy with TGF-β and PD-L1 inhibitors. (PubMed, Mol Ther Oncol)

Anti-mouse CLDN18.2 CAR-T cells suppressed tumor growth of mice bearing the syngeneic graft of S6M but not the CLDN18.2-low S1M cell line. Dual inhibition of immunosuppressive molecules TGF-β and PD-L1 enhanced the in vivo efficacy of anti-mouse CLDN18.2 CAR-T against S6M cells by recruiting NK cells to tumor microenvironment, suggesting the potential utility of our novel syngeneic gastric cancer cell line model in designing innovative clinical therapeutic approaches.

8 days ago

Preclinical • Journal

PD-L1 (Programmed death ligand 1) • TP53 (Tumor protein P53) • CLDN18 (Claudin 18) • SMAD4 (SMAD family member 4) • CDH1 (Cadherin 1) • TGFB1 (Transforming Growth Factor Beta 1) • PDX1 (Pancreatic And Duodenal Homeobox 1)

A Study of IDE892 as Monotherapy and Combination in MTAP-deleted Advanced Solid Tumors (clinicaltrials.gov)

P1, N=260, Recruiting, IDEAYA Biosciences | Not yet recruiting --> Recruiting

8 days ago

Enrollment open

MTAP (Methylthioadenosine Phosphorylase)

MTAP deletion

IDE397

Clinicopathological and molecular mechanisms of CLDN18.2 in gastric cancer aggressiveness: a high-risk population study with multi-omics profiling. (PubMed, J Pathol Transl Med)

CLDN18.2 overexpression is associated with poor prognosis in GC patients. Transcriptomic and proteomic analyses demonstrate that CLDN18.2 promotes tumor progression and metastasis, underscoring its potential as an independent prognostic factor in regions with a high incidence of GC.

9 days ago

Journal • IO biomarker

HER-2 (Human epidermal growth factor receptor 2) • MSI (Microsatellite instability) • CLDN18 (Claudin 18) • MLH1 (MutL homolog 1) • MSH6 (MutS homolog 6) • MSH2 (MutS Homolog 2) • PMS2 (PMS1 protein homolog 2)

CLDN18.2 positive

Personalized Cancer Vaccine (PCV) Strategy in Patients With Solid Tumors and Molecular Residual Disease (clinicaltrials.gov)

P1, N=32, Recruiting, Washington University School of Medicine | N=16 --> 32

9 days ago

Enrollment change

Signatera™

Hiltonol (poly-ICLC)

10d

Neoadjuvant Intra-tumoral RP2 and FLOT in Gastroesophageal Adenocarcinoma (clinicaltrials.gov)

P2, N=34, Not yet recruiting, Abramson Cancer Center at Penn Medicine | Initiation date: Nov 2025 --> Apr 2026

10 days ago

Trial initiation date

docetaxel • 5-fluorouracil • oxaliplatin • leucovorin calcium • Neulasta (pegfilgrastim) • Neupogen (filgrastim) • sturlimogene erparepvec (RP2)